A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis

A D Fraser, A W R van Kuijk, R Westhovens, Z Karim, R Wakefield, A H Gerards, R Landewé, S D Steinfeld, P Emery, B A C Dijkmans, D J Veale, A D Fraser, A W R van Kuijk, R Westhovens, Z Karim, R Wakefield, A H Gerards, R Landewé, S D Steinfeld, P Emery, B A C Dijkmans, D J Veale

Abstract

Objectives: To evaluate the safety and efficacy of adding ciclosporin A (CSA) to the treatment of patients with psoriatic arthritis (PsA) demonstrating an incomplete response to methotrexate (MTX) monotherapy.

Methods: In a 12 month, randomised, double blind, placebo controlled trial at five centres in three countries, 72 patients with active PsA with an incomplete response to MTX were randomised to receive either CSA (n = 38) or placebo (n = 34). Patients underwent full clinical and radiological assessment and, in addition, high resolution ultrasound (HRUS) was performed at one centre. An intention to treat (last observation carried forward) analysis was employed.

Results: Some significant improvements were noted at 12 months in both groups. However, in the active but not the placebo arm there were significant improvements in swollen joint count, mean (SD), from 11.7 (9.7) to 6.7 (6.5) (p<0.001) and C reactive protein, from 17.4 (14.5) to 12.7 (14.3) mg/l (p<0.05) as compared with baseline. The Psoriasis Area and Severity Index (PASI) score improved in the active group (2 (2.3) to 0.8 (1.3)) as compared with placebo (2.2 (2.7) to 1.9 (2.8)), p<0.001, and synovitis detected by HRUS (33 patients, 285 joints) was reduced by 33% in the active group compared with 6% in the placebo group (p<0.05). No improvement in Health Assessment Questionnaire or pain scores was detected.

Conclusions: Synovitis detected by HRUS was significantly reduced. Combining CSA and MTX treatment in patients with active PsA, and a partial response to MTX, significantly improves the signs of inflammation but not pain or quality of life.

Figures

Figure 1
Figure 1
Changes in clinical, biochemical, and radiological measurements between baseline and 48 weeks. Significant changes from baseline are indicated (*p

Figure 2

Percentage of joints with synovitis…

Figure 2

Percentage of joints with synovitis detectable by HRUS from baseline to 48 weeks.…

Figure 2
Percentage of joints with synovitis detectable by HRUS from baseline to 48 weeks. *p
Similar articles
Cited by
References
    1. J Rheumatol. 2001 Oct;28(10):2274-82 - PubMed
    1. JAMA. 1964 Sep 7;189:743-7 - PubMed
    1. J Rheumatol. 2003 Feb;30(2):260-8 - PubMed
    1. BioDrugs. 2003;17(4):263-70 - PubMed
    1. N Engl J Med. 2003 Aug 14;349(7):658-65 - PubMed
Show all 34 references
Publication types
MeSH terms
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Figure 2
Figure 2
Percentage of joints with synovitis detectable by HRUS from baseline to 48 weeks. *p

References

    1. J Rheumatol. 2001 Oct;28(10):2274-82
    1. JAMA. 1964 Sep 7;189:743-7
    1. J Rheumatol. 2003 Feb;30(2):260-8
    1. BioDrugs. 2003;17(4):263-70
    1. N Engl J Med. 2003 Aug 14;349(7):658-65
    1. Semin Arthritis Rheum. 2003 Aug;33(1):29-37
    1. Arthritis Rheum. 2003 Nov;48(11):3085-95
    1. Rheumatology (Oxford). 2003 Dec;42(12):1460-8
    1. Acta Radiol Diagn (Stockh). 1977 Jul;18(4):481-91
    1. Dermatologica. 1978;157(4):238-44
    1. J Rheumatol. 1982 Sep-Oct;9(5):789-93
    1. Acta Derm Venereol. 1983;63(2):165-7
    1. Arthritis Rheum. 1984 Apr;27(4):376-81
    1. Acta Derm Venereol. 1987;67(3):270-3
    1. Q J Med. 1987 Feb;62(238):127-41
    1. Arch Dermatol. 1989 Apr;125(4):507-10
    1. J Rheumatol. 1990 Jun;17(6):809-12
    1. J Rheumatol. 1992 Jun;19(6):872-7
    1. Allerg Immunol (Paris). 1992 Dec;24(10):393-4
    1. Dermatology. 1993;186(1):62-7
    1. Arthritis Rheum. 1993 Jun;36(6):729-40
    1. Br J Rheumatol. 1994 Feb;33(2):133-8
    1. Acta Derm Venereol Suppl (Stockh). 1994;186:116-7
    1. Acta Derm Venereol Suppl (Stockh). 1994;186:94-5
    1. N Engl J Med. 1995 Jul 20;333(3):137-41
    1. Clin Exp Rheumatol. 1995 Sep-Oct;13(5):589-93
    1. Br J Dermatol. 1996 Nov;135(5):752-7
    1. Curr Opin Rheumatol. 1997 Jul;9(4):295-301
    1. Arthritis Rheum. 1997 Oct;40(10):1868-72
    1. Exp Hematol. 1998 Dec;26(13):1215-22
    1. Arthritis Rheum. 1999 Jun;42(6):1232-45
    1. Br J Dermatol. 1999 Aug;141(2):279-82
    1. Ann Rheum Dis. 1999 Oct;58(10):595-7
    1. Arthritis Rheum. 2002 Jan;46(1):124-9

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi